Oculis (OCS) Competitors

Organogenesis (NASDAQ:ORGO) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, community ranking, earnings, profitability, risk and institutional ownership.

Which has higher earnings and valuation, ORGO or OCS?

Organogenesis has higher revenue and earnings than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$450.89M	0.80	$15.53M	$0.10	27.30
Oculis	$960K	378.68	-$40.55M	N/A	N/A

Does the media favor ORGO or OCS?

In the previous week, Organogenesis had 1 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Oculis. Organogenesis' average media sentiment score of 1.36 beat Oculis' score of 1.29 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer ORGO or OCS?

Organogenesis received 82 more outperform votes than Oculis when rated by MarketBeat users. However, 78.57% of users gave Oculis an outperform vote while only 65.49% of users gave Organogenesis an outperform vote.

Company	Underperform	Outperform
Organogenesis	Outperform Votes 93 65.49%	Underperform Votes 49 34.51%
Oculis	Outperform Votes 11 78.57%	Underperform Votes 3 21.43%

Do institutionals & insiders believe in ORGO or OCS?

39.5% of Organogenesis shares are owned by institutional investors. Comparatively, 14.3% of Oculis shares are owned by institutional investors. 34.0% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is ORGO or OCS more profitable?

Organogenesis has a net margin of 2.90% compared to Organogenesis' net margin of 0.00%. Oculis' return on equity of 4.83% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	2.90%	4.83%	2.88%
Oculis	N/A	N/A	N/A

Do analysts rate ORGO or OCS?

Organogenesis currently has a consensus target price of $3.75, suggesting a potential upside of 37.36%. Oculis has a consensus target price of $34.00, suggesting a potential upside of 240.34%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Oculis	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Organogenesis beats Oculis on 9 of the 15 factors compared between the two stocks.